Literature DB >> 15117985

Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies.

Stephen K Chia1, Caroline H Speers, Cicely J Bryce, Malcolm M Hayes, Ivo A Olivotto.   

Abstract

PURPOSE: To discuss the absolute benefits from adjuvant systemic therapy knowledge of long-term outcomes and baseline risks of relapse and disease-specific survival are required. We assessed the 10-year outcomes in a population-based cohort of node-negative (N-) lymphovascular negative (LV-) early breast cancers diagnosed from 1989 to 1991 who did not receive adjuvant systemic therapy.
METHODS: One thousand one hundred eighty-seven cases of pT(1-2)N(0) LV- breast cancers with a median follow-up of 10.4 years were reviewed. Kaplan-Meier survival curves for relapse free survival (RFS), breast cancer-specific survival (BCSS) and overall survival (OS) were compared with log-rank tests with cohorts stratified for tumor size and grade.
RESULTS: The median age of this series was 62 years. Four hundred thirty tumors were < or = 1 cm in diameter (cohort 1), 507 were 1.1-2 cm (cohort 2), and 250 were 2.1 to 5 cm in diameter (cohort 3). The 10-year outcomes for cohorts 1, 2, and 3, respectively, were significantly different: RFS, 82%, 75%, and 66%; BCSS, 92%, 90%, and 77%; and OS, 79%, 78%, and 66%. Tumor grade significantly altered outcome within size cohorts, particularly in pT(1)N(0) breast cancers.
CONCLUSION: This study provides detailed information on the continued relapse and breast cancer death rate to 10 years of follow-up. Specifically, without adjuvant systemic therapy, patients with LV-, N - breast cancer had a > or = 25% 10-year risk of relapse and a corresponding 10-year breast cancer death rate of > or = 10% if they had either a grade 3 tumor < or = 1 cm, a grade 2 to 3 tumor from 1.1 to 2 cm, or any grade tumor greater than 2 cm.

Entities:  

Mesh:

Year:  2004        PMID: 15117985     DOI: 10.1200/JCO.2004.09.070

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  35 in total

1.  Breast Centers in Germany.

Authors:  Ute-Susann Albert; Uwe Wagner; Matthias Kalder
Journal:  Breast Care (Basel)       Date:  2009-08-14       Impact factor: 2.860

2.  Node-Negative Breast Cancer: Which Patients Should Be Treated?

Authors:  Marcus Schmidt
Journal:  Breast Care (Basel)       Date:  2008-08-20       Impact factor: 2.860

Review 3.  Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.

Authors:  Stefan Paepke; Volker R Jacobs; Ralf Ohlinger; Mathias Warm; Sherko Kümmel; Anke Thomas; Nadia Harbeck; Marion Kiechle-Bahat
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-06       Impact factor: 4.553

4.  Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.

Authors:  Ines Vaz-Luis; Melissa E Hughes; Angel M Cronin; Hope S Rugo; Stephen B Edge; Beverly Moy; Richard L Theriault; Michael J Hassett; Eric P Winer; Nancy U Lin
Journal:  Cancer       Date:  2015-03-10       Impact factor: 6.860

5.  Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer.

Authors:  Motonobu Saito; Akiteru Goto; Noriko Abe; Katsuharu Saito; Daichi Maeda; Tohru Ohtake; Yoshinori Murakami; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

6.  Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.

Authors:  Jennifer Y Wo; Kun Chen; Bridget A Neville; Nancy U Lin; Rinaa S Punglia
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

7.  Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.

Authors:  G Houvenaeghel; A Goncalves; J M Classe; J R Garbay; S Giard; H Charytensky; M Cohen; C Belichard; C Faure; S Uzan; D Hudry; P Azuar; R Villet; P Gimbergues; C Tunon de Lara; M Martino; E Lambaudie; C Coutant; F Dravet; M P Chauvet; E Chéreau Ewald; F Penault-Llorca; B Esterni
Journal:  Ann Oncol       Date:  2014-01-07       Impact factor: 32.976

Review 8.  The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.

Authors:  Josee-Lyne Ethier; Eitan Amir
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

9.  Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.

Authors:  Ossama Tawfik; Bruce F Kimler; Marilyn Davis; Christopher Stasik; Sue-Min Lai; Matthew S Mayo; Fang Fan; John K Donahue; Ivan Damjanov; Patricia Thomas; Carol Connor; William R Jewell; Holly Smith; Carol J Fabian
Journal:  Virchows Arch       Date:  2007-04-26       Impact factor: 4.064

10.  Effect of large tumor size on cancer-specific mortality in node-negative breast cancer.

Authors:  Ke-Da Yu; Yi-Zhou Jiang; Sheng Chen; Zhi-Gang Cao; Jiong Wu; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Mayo Clin Proc       Date:  2012-12       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.